Business Context and Reporting Period
This Form 8-K is a current report filed by Klotho Neurosciences, Inc. (not Greenland Mines Ltd) on June 16, 2025. The registrant is a Delaware corporation with principal executive offices in Omaha, NE. The filing addresses regulatory compliance with Nasdaq listing standards and recent capital raising activities.
Key Financial Metrics
- Capital Raised: Approximately $11 million in proceeds received from the exercise of outstanding warrants between June 8, 2025, and June 13, 2025.
- Stockholders' Equity: Management believes equity is now in excess of the $2.5 million minimum Nasdaq requirement following the warrant exercises.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or margins.
- Debt and Liquidity: Specific debt levels and liquidity ratios are not disclosed in this report.
Material Changes
The primary material change is the receipt of $11 million from warrant exercises, which directly impacts the company's stockholders' equity. This capital infusion is intended to resolve a deficiency in meeting the Nasdaq minimum stockholders' equity requirement of $2.5 million.
Outlook, Risks, and Management Commentary
- Compliance Status: The company intends to notify Nasdaq of its compliance status to seek a determination that it has regained compliance with continued listing standards.
- Uncertainty: Management explicitly states there can be no assurance that Nasdaq will determine the company has regained compliance.
- Forward-Looking Statements: The filing contains standard disclaimers regarding future commercial operations, noting that actual results may differ materially due to risks such as the inability to implement business plans or changes in the regulatory environment.
Investor Verification Checklist
- Verify the official Nasdaq determination regarding the company's compliance with the $2.5 million stockholders' equity requirement.
- Confirm the exact number of shares issued upon the exercise of warrants to assess potential dilution.
- Review the attached Press Release (Exhibit 99.1) for additional details on the use of proceeds and future operational plans.
- Check subsequent filings for any updates on the Nasdaq listing status or further capital requirements.